Does the media favor BDSX or CSTL?

In the previous week, Biodesix had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Biodesix and 5 mentions for Castle Biosciences. Biodesix's average media sentiment score of 1.06 beat Castle Biosciences' score of 0.92 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Castle Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, BDSX or TALK?

Talkspace has higher revenue and earnings than Biodesix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.22 -$35.26M -$3.17 N/A Talkspace $228.87M 3.84 $7.79M N/A N/A

Is BDSX or TALK more profitable?

Talkspace has a net margin of 0.08% compared to Biodesix's net margin of -26.97%. Talkspace's return on equity of 0.17% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Talkspace 0.08% 0.17% 0.14%

Does the media refer more to BDSX or TALK?

In the previous week, Biodesix had 5 more articles in the media than Talkspace. MarketBeat recorded 6 mentions for Biodesix and 1 mentions for Talkspace. Biodesix's average media sentiment score of 1.06 beat Talkspace's score of 0.00 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Talkspace 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BDSX or GMRS more profitable?

GMR Solutions has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. GMR Solutions' return on equity of 0.00% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% GMR Solutions N/A N/A N/A

Does the media favor BDSX or GMRS?

In the previous week, GMR Solutions had 1 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for GMR Solutions and 6 mentions for Biodesix. GMR Solutions' average media sentiment score of 1.34 beat Biodesix's score of 1.06 indicating that GMR Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GMR Solutions 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BDSX or FLGT more profitable?

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -26.97%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% Fulgent Genetics -26.05% -4.93% -4.50%

Does the media refer more to BDSX or FLGT?

In the previous week, Biodesix had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 6 mentions for Biodesix and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Biodesix's score of 1.06 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer BDSX or ?

Biodesix presently has a consensus price target of $31.33, indicating a potential upside of 16.18%. Given Biodesix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biodesix is more favorable than . Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodesix 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, BDSX or ?

has lower revenue, but higher earnings than Biodesix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodesix $88.50M 3.22 -$35.26M -$3.17 N/A N/A N/A N/A N/A N/A

Is BDSX or more profitable?

has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. 's return on equity of 0.00% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Biodesix -26.97% -788.19% -30.33% N/A N/A N/A

Does the media prefer BDSX or ?

In the previous week, had 1307 more articles in the media than Biodesix. MarketBeat recorded 1313 mentions for and 6 mentions for Biodesix. Biodesix's average media sentiment score of 1.06 beat 's score of 0.00 indicating that Biodesix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biodesix 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 298 Very Positive mention(s) 291 Positive mention(s) 375 Neutral mention(s) 238 Negative mention(s) 111 Very Negative mention(s) Neutral

Biodesix (BDSX) Competitors

$26.97 +0.93 (+3.57%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$27.40 +0.43 (+1.61%)

As of 09/11/2026 07:54 PM Eastern

Compare

BDSX vs. CSTL, TALK, GMRS, FLGT, and TOI

Should you buy Biodesix stock or one of its competitors? Biodesix's main competitors and comparable companies include Castle Biosciences (CSTL), Talkspace (TALK), GMR Solutions (GMRS), Fulgent Genetics (FLGT), and Oncology Institute (TOI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Biodesix compare to Castle Biosciences?

Biodesix (NASDAQ:BDSX) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Biodesix had 1 more articles in the media than Castle Biosciences. MarketBeat recorded 6 mentions for Biodesix and 5 mentions for Castle Biosciences. Biodesix's average media sentiment score of 1.06 beat Castle Biosciences' score of 0.92 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.0% of Biodesix shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 6.1% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Castle Biosciences has a net margin of -5.43% compared to Biodesix's net margin of -26.97%. Castle Biosciences' return on equity of -4.15% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Castle Biosciences	-5.43%	-4.15%	-3.45%

Biodesix has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Biodesix currently has a consensus price target of $31.33, indicating a potential upside of 16.18%. Castle Biosciences has a consensus price target of $42.00, indicating a potential upside of 29.91%. Given Castle Biosciences' higher probable upside, analysts plainly believe Castle Biosciences is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Castle Biosciences	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.22	-$35.26M	-$3.17	N/A
Castle Biosciences	$344.23M	2.87	-$24.16M	-$0.66	N/A

Summary

Castle Biosciences beats Biodesix on 10 of the 15 factors compared between the two stocks.

How does Biodesix compare to Talkspace?

Biodesix (NASDAQ:BDSX) and Talkspace (NASDAQ:TALK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Biodesix has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Talkspace has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

21.0% of Biodesix shares are held by institutional investors. Comparatively, 57.4% of Talkspace shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 23.5% of Talkspace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biodesix had 5 more articles in the media than Talkspace. MarketBeat recorded 6 mentions for Biodesix and 1 mentions for Talkspace. Biodesix's average media sentiment score of 1.06 beat Talkspace's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Talkspace	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Talkspace has a net margin of 0.08% compared to Biodesix's net margin of -26.97%. Talkspace's return on equity of 0.17% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Talkspace	0.08%	0.17%	0.14%

Biodesix currently has a consensus price target of $31.33, indicating a potential upside of 16.18%. Talkspace has a consensus price target of $5.56, indicating a potential upside of 5.95%. Given Biodesix's stronger consensus rating and higher possible upside, equities analysts plainly believe Biodesix is more favorable than Talkspace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Talkspace	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Talkspace has higher revenue and earnings than Biodesix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.22	-$35.26M	-$3.17	N/A
Talkspace	$228.87M	3.84	$7.79M	N/A	N/A

Summary

Talkspace beats Biodesix on 9 of the 15 factors compared between the two stocks.

How does Biodesix compare to GMR Solutions?

Biodesix (NASDAQ:BDSX) and GMR Solutions (NYSE:GMRS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Biodesix currently has a consensus price target of $31.33, indicating a potential upside of 16.18%. GMR Solutions has a consensus price target of $18.78, indicating a potential upside of 46.59%. Given GMR Solutions' higher probable upside, analysts clearly believe GMR Solutions is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
GMR Solutions	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.70

In the previous week, GMR Solutions had 1 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for GMR Solutions and 6 mentions for Biodesix. GMR Solutions' average media sentiment score of 1.34 beat Biodesix's score of 1.06 indicating that GMR Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GMR Solutions	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GMR Solutions has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.22	-$35.26M	-$3.17	N/A
GMR Solutions	N/A	N/A	N/A	-$1.56	N/A

21.0% of Biodesix shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GMR Solutions has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. GMR Solutions' return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
GMR Solutions	N/A	N/A	N/A

Summary

GMR Solutions beats Biodesix on 9 of the 13 factors compared between the two stocks.

How does Biodesix compare to Fulgent Genetics?

Biodesix (NASDAQ:BDSX) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -26.97%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
Fulgent Genetics	-26.05%	-4.93%	-4.50%

Biodesix presently has a consensus target price of $31.33, indicating a potential upside of 16.18%. Fulgent Genetics has a consensus target price of $27.50, indicating a potential upside of 34.47%. Given Fulgent Genetics' higher possible upside, analysts clearly believe Fulgent Genetics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

21.0% of Biodesix shares are held by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 36.2% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biodesix has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Biodesix has higher earnings, but lower revenue than Fulgent Genetics. Biodesix is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.22	-$35.26M	-$3.17	N/A
Fulgent Genetics	$323.93M	1.74	-$60.51M	-$2.82	N/A

In the previous week, Biodesix had 3 more articles in the media than Fulgent Genetics. MarketBeat recorded 6 mentions for Biodesix and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.62 beat Biodesix's score of 1.06 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Fulgent Genetics beats Biodesix on 11 of the 17 factors compared between the two stocks.

How does Biodesix compare to ?

Biodesix (NASDAQ:BDSX) and (:) are related companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, had 1307 more articles in the media than Biodesix. MarketBeat recorded 1313 mentions for and 6 mentions for Biodesix. Biodesix's average media sentiment score of 1.06 beat 's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
	298 Very Positive mention(s)	291 Positive mention(s)	375 Neutral mention(s)	238 Negative mention(s)	111 Very Negative mention(s)	Neutral

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. 's return on equity of 0.00% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-26.97%	-788.19%	-30.33%
	N/A	N/A	N/A

has lower revenue, but higher earnings than Biodesix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$88.50M	3.22	-$35.26M	-$3.17	N/A
	N/A	N/A	N/A	N/A	N/A

Biodesix presently has a consensus price target of $31.33, indicating a potential upside of 16.18%. Given Biodesix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Biodesix is more favorable than .

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Biodesix beats on 8 of the 12 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDSX vs. The Competition

Export

Metric	Biodesix	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$284.51M	$9.84B	$7.16B	$12.85B
Dividend Yield	N/A	2.61%	2.57%	11.72%
P/E Ratio	-8.51	33.53	274.94	25.36
Price / Sales	3.22	4.89	685.43	116.41
Price / Cash	N/A	125.15	76.65	51.52
Price / Book	-87.00	5.29	10.33	6.20
Net Income	-$35.26M	$313.25M	$3.50B	$358.50M
7 Day Performance	3.02%	-1.26%	-3.32%	-2.35%
1 Month Performance	13.37%	-1.53%	-0.53%	-3.23%
1 Year Performance	7,090.08%	58.44%	23.51%	8.79%

Biodesix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDSX Biodesix	3.7942 of 5 stars	$26.97 +3.6%	$31.33 +16.2%	+259.5%	$284.51M	$88.50M	N/A	220	Positive News Analyst Upgrade
CSTL Castle Biosciences	2.6066 of 5 stars	$33.33 +0.9%	$42.00 +26.0%	+50.9%	$1.02B	$344.23M	N/A	540
TALK Talkspace	1.4981 of 5 stars	$5.25 flat	$5.56 +6.0%	N/A	$879.43M	$228.87M	N/A	500
GMRS GMR Solutions	4.5205 of 5 stars	$12.97 +6.7%	$18.67 +43.9%	N/A	$700.64M	N/A	N/A	N/A	News Coverage Analyst Forecast
FLGT Fulgent Genetics	3.4841 of 5 stars	$19.65 +1.4%	$27.50 +40.0%	-6.5%	$540.24M	$322.67M	N/A	1,315

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biodesix (BDSX) Competitors

BDSX vs. CSTL, TALK, GMRS, FLGT, and TOI

How does Biodesix compare to Castle Biosciences?

Summary

How does Biodesix compare to Talkspace?

Summary

How does Biodesix compare to GMR Solutions?

Summary

How does Biodesix compare to Fulgent Genetics?

Summary

How does Biodesix compare to ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biodesix (BDSX) Competitors

BDSX vs. CSTL, TALK, GMRS, FLGT, and TOI

How does Biodesix compare to Castle Biosciences?

Does the media favor BDSX or CSTL?

Do insiders and institutionals have more ownership in BDSX or CSTL?

Is BDSX or CSTL more profitable?

Which has more risk & volatility, BDSX or CSTL?

Do analysts recommend BDSX or CSTL?

Which has preferable earnings and valuation, BDSX or CSTL?

Summary

How does Biodesix compare to Talkspace?

Which has more volatility and risk, BDSX or TALK?

Do institutionals and insiders have more ownership in BDSX or TALK?

Does the media refer more to BDSX or TALK?

Is BDSX or TALK more profitable?

Do analysts recommend BDSX or TALK?

Which has better earnings & valuation, BDSX or TALK?

Summary

How does Biodesix compare to GMR Solutions?

Do analysts rate BDSX or GMRS?

Does the media favor BDSX or GMRS?

Which has preferable earnings & valuation, BDSX or GMRS?

Do insiders & institutionals have more ownership in BDSX or GMRS?

Is BDSX or GMRS more profitable?

Summary

How does Biodesix compare to Fulgent Genetics?

Is BDSX or FLGT more profitable?

Do analysts rate BDSX or FLGT?

Do insiders and institutionals have more ownership in BDSX or FLGT?

Which has more volatility & risk, BDSX or FLGT?

Which has stronger valuation & earnings, BDSX or FLGT?

Does the media refer more to BDSX or FLGT?

Summary

How does Biodesix compare to ?

Does the media prefer BDSX or ?

Do insiders & institutionals believe in BDSX or ?

Is BDSX or more profitable?

Which has stronger earnings & valuation, BDSX or ?

Do analysts prefer BDSX or ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDSX vs. The Competition

Biodesix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools